pre drugs ko

7/29/2019 Pre Drugs Ko

1/12

DRUGS REQUIRING SPECIAL HANDLING

BIOLOGICAL PRODUCTS

STRENGTH/FORM DOSAGE COMMENTS

Hepatitis B vaccine Children: 5

mcg/0.5 mL of

HBsAg in a 0.5 mL

single-dose vial

Adult: 10 mcg/mL

of HBsAg in a 1 mL

single-dose vial

Dialysis: 40

mcg/mL of HBsAg

in a 1 mL single-

dose vial

20 yrs: 1.0 mL

Hepa B vaccine should be

administered intramuscularly.

Do not inject intravenously or

intradermally

Diptheria and Tetanus

Toxoid and acellular

pertusis vaccine

Each 0.5mL VIAL

contains: -2 IU (2.5

Lf U) of diphtheria

toxoid

- 20 IU (5 Lf U) of

tetanus toxoid

-8 mcg of pertussis

toxoid,

- 8 mcg of

filamentous

haemagglutinin

and 2.5 mcg of

pertactin

0.5 mL BOOSTRIX is administered by

deep intramuscular injection,

preferably in the deltoid region

THE VACCINE SHOULD NEVER

BE ADMINISTERED

INTRAVENOUSLY.

Haemophilus influenza

type b (Hib) conjugate

vaccine

Single dose vial 0.5 mL Hib is injected into the upper le

muscle in infants under 12

months of age. In children over

12 months of age the injection

will be given in the upper arm

muscle.

First dose: 2 months of age

Second dose: 4 months of age

Third dose: 6 months of age.

To ensure long term protection booster dose is generally given

in the second year of life .

Inacctivated Polio virus

vaccine (IPV)

Single-dose vials

and prefilled

syringes containing

a 0.5-mL

0.5 mL Children

Primary series consists of 3

doses of 0.5 mL. Separate first 2

doses by at least 4 weeks, but


2/12

suspension for

injection.

preferably 8 weeks; commonly

given at 2 and 4 mo. Give third

dose at least 6 months, but

preferably 12 months, after

second dose, commonly given a

15 to 18 mo.

Adults

For unvaccinated adults at

increased risk of exposure to

poliovirus, give primary series o

IPV: 2 doses at 1 to 2-mo

interval, with third dose 6 to 12

months later. If less than 3

months, but older than 2 month

remain before protection is

needed (e.g., planned

international travel), give 3

doses of IPV at least 1 month

apart.

Measles ,mumps ,and

rubella vaccine (MMR)

Each 0.5mL dose

contains not less

than:

-103.0 CCID50 (cell

culture infectious

dose 50%) of the

Schwarz measles

-103.7 CCID50 of

the RIT 4385

mumps, and-103.0 CCID50 of

the Wistar RA 27/3

rubella virus

Strains

vial

0.5 mL This vaccine is injected under

the skin (subcutaneously) or

into muscle. PRIORIX is

generally injected into the uppe

leg muscle in infants under 12

months of age. In children over

12 months of age and older

children and adults the injection

3

This may be given in the upper

arm muscle.

Varicella Vaccine Each 0.5mL dose

contains not less

than 103.3 plaque-

forming units of the

varicella-zostervirus.

vial

0.5 mL injected under the skin

(subcutaneously) of the

shoulder or thigh.

The vaccine should never be

given intravenously.

In children from 9 months up to

and including 12 years, the

appropriate time and number o

doses that will be given will be

determined by your doctor on

the basis of appropriate official

recommendations. Adults and


3/12

adolescents aged 13 years and

older are generally given two

doses at least six weeks apart.

Each dose is given at a separate

visit.

The need for booster doses is

uncertain at present.

Pneumococcal Vaccine 0.5ml dose of

SYNFLORIX

contains 1

microgram of

Pneumococcal

polysaccharide

serotypes 1, 5, 6B,

7F, 9V, 14 and

23F and 3

micrograms of

Pneumococcal

polysaccharide

serotypes 4, 18C

and 19F.

0.5 mL Usually, your child will receive

three injections with an interva

of

at least one month between eac

one. The first injection can be

given from the age of 6 weeks

onwards. At least six months

after

the third injection, your child

will

receive an additional injection.

(booster)

Hepatitis A Vaccine 0.5-mL single-dose

vials and prefilled

syringes.

1-mL single-dose

vials and prefilled

syringes

19 yrs; 1.0

mL

HAV should be administered by

intramuscular injection only.

HAVRIX should not be

administered in the gluteal

region; such injections may

result in suboptimal response.

Do not administer this product

intravenously, intradermally, orsubcutaneously

Influenza Vaccine IM injection 0.5 mL The Centers for Disease Control

and Prevention (CDC)

recommend that everyone 6

months and older should receiv

the flu vaccine.

Anthrax vaccine

adsorbed(biothrax)

5.0 mL multidose

vials containing

ten 0.5 mL doses.

5mL Vial Biothrax is given to patient

ntramuscularly.

Digoxin Immune Fab,ovine

(digiblind)

Each vial, which

will bind

approximately

0.5 mg of digoxin

(or digitoxin),

contains 38 mg of

digoxin-specific

Fab fragments

derived from

sheep plus 75 mg

0.5 mg each vial Ingestion of more than 10 mg of

digoxin in previously healthy

adults or 4 mg of digoxin in

previously healthy children, or

ingestion causing steady-state

serum concentrations greater

than 10 ng/mL, often results in

cardiac arrest


4/12

of sorbitol as a

stabilizer and

28 mg of sodium

chloride.

Diptheria Toxoid /Tetanus

toxoid/Acellular Pertussis

vaccine adsorbed

Daptacel,infanrix,tripedia)

Each 0.5 mL

Diphtheria toxoid

not 1 year of age, the

deltoid is the preferred site since

use of the anterolateral thigh

results in frequent complaints of

limping due to muscle pain.13

After insertion of the needle,

aspirate to ensure that the needl

has not entered a blood vessel.

Do not inject IV

Hepatitis A vaccine

(Inactivated)

160/ 80 pre-filled

syringe

(inj) 160 antigen

units/0.5 mL

80 antigen

units/0.5 mL

0.5-mL pediatric

dose in single-dose

vials and prefilled

syringes. 1-mL

adult dose in

single-dose vials

For intramuscular administratio

only.

Children/Adolescents:

vaccination consists of a 0.5-mL

primarydose administered

intramuscularly, and a 0.5-mL


5/12

(Avaxim) and prefilled

syringes

booster doseadministered

intramuscularly 6 to 18 months

later.

Adults: vaccination consists of a

1-mL primary dose administered

intramuscularly, and a 1-mL

booster dose administeredIntramuscularly 6 to 18 months

later.

Hepatitis B immune

globulin(Bay Hep,Nabi-

HB)

1 mL dose in a

single-use vial

(>312 IU)

5 mL dose in a

single-use vial

(>1560 IU)

0.5mL This product is for intramuscula

use only.

The use of this product by the

intravenous route is not

indicated.

Hepatitis B vaccine

Recombinant(engerix

B,Recombivax HB

Vaccine inj 10

mcg/0.5 mL

(monodose,

pediatric dose). 20

mcg/mL

(monodose, adult

dose).

A 1.0 mL dose of

the formulation of

the vaccine for use

in

dialysis/predialysis

patients contains

40 mcg of HBsAg

IMAdult20 yr20 mcg/dose.

Neonate, infant & childn19 yr10

mcg/dose.

Immune globulin Human

(Bay Gam)

2 mL and 10 mL

single dose vials.

2 mL and 10 mL 20 IU/kg body wt IM as a single

dose.

Immune Globulin

Intravenous Human

(sandoglobuli IV)

white lyophilized

powder in 1, 3, 6

and 12 g size vials.

The only diluents

which may be

used toreconstitute the

product are sterile

(0.9%) Sodium

Chloride Injection

USP, 5% Dextrose,

or Sterile Water.

The product should

be infused at a rate

less than 2 mg

Ig/kg/min.

Replacement therapy in

primary immunodeficiency Initia

dose: 0.4-0.8 g/kg body wt

followed by 0.2-0.8 g/kg body w

every 2-4 wk to obtain IgG troug

level of at least 4-6g/L. Replacement therapy in

secondary immunodeficiency 0.2

0.4 g/kg body wt every 3-4 wk to

obtain IgG trough level of at leas

4-6 g/L.Replacement therapy in

childn w/ AIDS 0.2-0.4 g/kg bod

wt every 3-4 wk.Idiopathic

thrombocytopenic purpura 0.8-1

g/kg body wt on day 1, repeated

once w/in 3 days or 0.4 g/kg

body wt/day for 2-5 days.

Influenza Virus vaccineSubviron (Fluvirin)

0.5 mL single-doseprefilled syringe

(3, 11) 5.0

mL multi-dose vial

containing 10

doses (each dose

is 0.5 mL) (3,11)

0.5 mL Adults and children aged fourand over: 0,5 mL by deep

subcutaneous or intramuscular

injection. Young children who

may not have been previously

infected, or who have not

received trivalent influenza

vaccine in the past four years,
https://www.mims.com/Philippines/diagnoses/Info/1207https://www.mims.com/Philippines/diagnoses/Info/1207https://www.mims.com/Philippines/diagnoses/Info/2680https://www.mims.com/Philippines/diagnoses/Info/3236https://www.mims.com/Philippines/diagnoses/Info/3236https://www.mims.com/Philippines/diagnoses/Info/3236https://www.mims.com/Philippines/diagnoses/Info/3236https://www.mims.com/Philippines/diagnoses/Info/2680https://www.mims.com/Philippines/diagnoses/Info/1207https://www.mims.com/Philippines/diagnoses/Info/1207


6/12

may require two doses of vaccin

given at an interval of 4 -

6 weeks, to ensure a protective

antibody response.

Influenza virus vaccine

(Flu shield,Fluzone)

Suspension for

injection in a

prefilled

microinjection

system, 0.1 mL

A single 0.1 mL

dose for

intradermal

injection in adults

18 through 64

years of age

IM or deep SC injAdult & childn

>36 mth 0.5 mL. Childn 6-35

mth Limited clinical data. Doses

of 0.25 mL or 0.5 mL have been

used. Childn who have not been

previously vaccinatedAdminister

a 2nd dose after an interval of at

least 4 wk.

Measles Virus Vaccine live

(attenuvax)

The reconstituted

vaccine is for

subcutaneous

administration.

Each 0.5 mL dose

contains not less

than 1,000 TCID50

(tissue culture

infectious doses)

of measles virus.

0.5 mL 0.5 mL administered

subcutaneously, preferably into

the outer aspect of the upper

arm.

The recommended age for

primary vaccination is 12 to 15

months.

Revaccination with M-M-RII is

recommended prior to

elementary school entry.

Children first vaccinated when

younger than 12 months of age

should receive another dose

between 12 to 15 months of age

followed by revaccination prior

to elementary school entry.

Measles/mumps/rubellavirus vaccine MMR11

The reconstitutedvaccine is for

subcutaneous

administration.

Each 0.5 mL dose

contains not less

than 1,000 TCID50

(tissue culture

infectious doses)

of measles virus..

Single 0.5-mL dose administered by SC/IM inj.The dose for any age is 0.5 mL

administered subcutaneously,

preferably into the outer aspect

of the upper arm.



months.





younger than 12 months of ageshould receive another dose

between 12to15 months of age


to elementary school entry.

Meningitis vaccine

(menomune)

Powd for inj

(monodose vial +

0.78 mL diluent)

0.5mL SCImmunization 0.5

mL. Revaccination for childn


7/12

Mumps Virus Vaccine

(mumps vax)

The reconstituted

vaccine is for

subcutaneous

administration.

Each 0.5 mL dose

contains not less

than 20,000TCID50 (tissue

culture infectious

doses) of mumps

virus.

0.5 mL The dose for any age is 0.5 mL

administered subcutaneously,

preferably into the outer aspect

of the upper arm.



months.

Individuals first vaccinated with

MUMPSVAX at 12months of age

or older should be revaccinated

with M-M-R*II (Measles, Mumps

and Rubella Virus Vaccine Live)

prior to elementary school entry

Revaccination may seroconvert

primary failures or boost

antibody titers of those

individuals whose titers have

declined.

Pneumococcal vaccine(

Diptheria Protein)-

Prevnar

Syringe, 1 Dose 0.5mL For infants, the immunization

series of Prevnar consists of

three doses of 0.5 mL each, at

approximately 2-month interval

followed by a fourth dose of 0.5

mL at 12-15 months of age. The

customary age for the first dose

is 2 months of age, but it can be

given as young as 6 weeks of age

The recommended dosing

interval is 4 to 8 weeks. Thefourth dose should be

administered at approximately

12-15 months of age, and at leas

2 months after the third dose.

Pneumococcal vaccine

(pneumovax 23-Pnu

immune23)

Vaccine 0.5 mL

(inj, single-dose

vial, clear,

colorless soln)

0.5 mL Primary immunization Single 0.5

mL inj. Reimmunization Single

0.5 mL inj. Must not be given

w/in 5 yr except for high-risk

subjects or those under

immunosuppressive therapy.

Administer IM or SC.

Polio vaccine Inacctivated(ipol)

Single-dose vialsand prefilled

syringes

containing a 0.5-

mL suspension for

injection.

0.5 mLChildrenPrimary series consists of 3 dose

of 0.5 mL. Separate first 2 doses

by at least 4 weeks, but

preferably 8 weeks; commonly

given at 2 and 4 mo. Give third

dose at least 6 months, but

preferably 12 months, after

second dose, commonly given at


8/12

15 to 18 mo.

Adults

For unvaccinated adults at

increased risk of exposure to

poliovirus, give primary series o

IPV: 2 doses at 1 to 2-mo interva

with third dose 6 to 12 monthslater. If less than 3 months, but

older than 2 months remain

before protection is needed (e.g.

planned international travel),

give 3 doses of IPV at least 1

month apart.

Rabies Immune vaccine

(Imovax/ rabavert)

One vial of freeze-

dried vaccine

containing a single

dose. - One sterile

syringe containing

diluent. A separate

plunger is

provided for

insertion and use.

- One sterile

disposable needle

for reconstitution.

1.0 mL For adults and older children, th

vaccine should be injected into

the deltoid muscle. In infants and

small children, the anterolateral

aspect of the thigh may be

preferable, depending on age an

body mass. Care should be taken

to avoid injection into or near

blood vessels and nerves. If bloo

or any suspicious discoloration

appears in the syringe, do not

inject but discard contents and

repeat procedure using a new

dose of vaccine at a different site

Respiratory Syncytial

Virus immune globulin

,Human(Respigam)

Injection, Solution 20 mL For preventing respiratory

syncytial virus (RSV) infection.

Adults and children 24 months oage and olderUse is not

recommended.

Infants and children younger

than 24 months of age750milligrams (mg) per kilogram

(kg) (340.9 mg per pound) of

body weight injected into a vein

once a month for five months.

Rho Immune Globulin

Human

1 prefilled single-

dose syringe of

RhoGAM

5 prefilled single-dose syringes of

RhoGAM

25 prefilled single-

dose syringes of

RhoGAM

50 g

300 g

For intramuscular use only. Do

not inject RhoGAM or

MICRhoGAM intravenously. In

the case of postpartum use, theproduct is intended for maternal

administration. Do not inject the

newborn infant.

Parenteral drug products should

be inspected visually for

particulate matter and

discoloration prior to

administration.


9/12

A single dose (approximately 50

g)* is contained in each prefille

syringe of MICRhoGAM. This dos

will suppress the immune

response to 2.5 mL of Rh-positiv

red blood cells. MICRhoGAM is

therefore indicated within 72hours after termination of

pregnancy up to and including 1

weeks gestation. At or beyond 1

weeks gestation, RhoGAM shoulbe administered instead of

MICRhoGAM.

A single dose (approximately 30

g) is contained in each prefilledsyringe of RhoGAM. This is the

usual dose for the indications

associated with pregnancy unles

there is clinical or laboratory

evidence of a fetal-maternal

hemorrhage (FMH) in excess of

15 mL of Rh-positive red blood

cells. RhoGAM should be

administered within 72 hours of

known or suspected exposure to

Rh-positive red blood cells.

Rubella Virus Vaccine Live

(attenuvax)

The reconstituted

vaccine is for

subcutaneous

administration.Each 0.5 mL dose

contains not less

than 1,000 TCID50

(tissue culture

infectious doses)

of measles virus..

0.5 mL 0.5 mL administered

subcutaneously, preferably into

the outer aspect of the upper

arm.The recommended age for


months.





younger than 12 months of age

should receive another dose

between 12 to 15 months of age


to elementary school entry.Tetanus and Diptheria

Toxoidsadsorbed(Td)

Single-dose (0.5

ml) vials.

Each 0.5 ml dose

of Td is

formulated to

contain the

following active

0.5 ml PRIMARY IMMUNIZATION

MassBiologics Td may be used inpersons 7 years of age and older

who have not been previously

immunized against tetanus and

diphtheria, as a primary

immunization series consisting o

three 0.5 ml doses. The first two


10/12

ingredients: 2 Lf of

tetanus toxoid and

2 Lf of diphtheria

toxoid.

doses are administered 4-8

weeks apart and the third dose i

administered 6-12 months after

the second dose.

Mass Biologics Td may be used

to complete the primary

immunization series for tetanusand diphtheria, following one or

two doses of Diphtheria and

Tetanus Toxoids and Pertussis

Vaccine Adsorbed (whole-cell

DTP), Diphtheria and Tetanus

Toxoids and A cellular Pertussis

Vaccine Adsorbed (DTaP) and/o

Diphtheria and Tetanus Toxoids

Adsorbed (DT) vaccine. Howeve

the safety and efficacy of

MassBiologics Td in such

regimens have not been

evaluated.

ROUTINE BOOSTER

IMMUNIZATION MassBiologicsTd may be used for routine

booster immunization against

tetanus and diphtheria in

persons 7 years of age and older

who have completed primary

immunization against tetanus

and diphtheria. Routine booster

immunization against tetanusand diphtheria is recommended

in children 11-12 years of age

and every 10 years thereafter.

Inject 0.5 ml of MassBiologics Tdintramuscularly. The preferred

site is the deltoid muscle. The

vaccine should not be injected

into the gluteal area or areas

where there may be a major

nerve trunk.

Do not administer this vaccine

intravenously, subcutaneously, ointradermally.

MassBiologics Td should not be

combined through reconstitution

or mixed with any other vaccine

Tetanus Immunoglobulin

(Bay Tet)

Vials containing

Human Tetanus

Immunoglobulin

equivalent to

250 I. U. / 500 I. U.

/ 1000 I. U

Prophylaxis :In High risk injuries

to non-immune and immune

patients (Above 7 Years)

In High risk injuries to non-


11/12

Tetanus antitoxin

250 / 500 / 1000

I.U

immune and immune patients

(Below 7 Years)

250 I.U. Deep IM 500 I.U. Deep IM

(if 24 hours have not passed

since injury or with a risk of

heavy contamination)

4 Units/kg or 250 I.U. Deep IMTherapeutic: Clinical tetanus

Newborn (Tetanus Neonatorum)

Children(Above 7 Years) &

Adults

250 I.U. to 500 I.U. IM and/or 25

I.U. intrathecal. 500 to 3,000 I.U.

IM and/or 500 I.U. intrathecal.

It should not be administered

intravenously.

Tetanus Toxoid

Tetanus toxoid adsorbed

purogenated

Each single dose of

0.5 mL,of ACEL-

IMUNE is

formulated to

contain9 Lf of

diphtheria toxoid

and 5 Lf of tetanus

toxoid (both

toxoids induce not

less than 2 units of

antitoxin per mL

in the guinea pig

potency test) and300

hemagglutinating

(HA) units of

acellular pertussis

vaccine.

0.5 mL Children who have recovered

from culture co & med pertussis

need not receive further doses o

a pertussis-containing vaccine7,

but should complete the

recommended series with

Diphtheria and Tetanus Toxoids

Adsorbed for pediatric USC(DT).

It is intended for active

immunization against diphtheria

tetanus, and pertussis. It is not to

be used for treatment of actual

infection.Ifa contraindicating event td the

pertussis vaccine component

occurs, Diphtheria and Tetanus

Toxoids, Adsorbed for pediatric

use (IX) should be substituted fo

each of the remaining doses. The

Advisory Committee on

Immunization Practices (ACID)

recommends that if an immediat

anaphylactic reaction occurs, no

further vaccination with any of

the three antigens in DTP shouldbe carried out.

If passive immunization is

required, Tetanus Immune

Globulin (TIG) or Diphtheria

Antitoxin are recommended.

Varicella virus vaccine

(varivax)

Suspension for

injection

0.5 mL Children (12 months to 12 years

of age)


12/12

(approximately

0.5-mL dose)

supplied as a

lyophilized

vaccine to be

reconstituted

using theaccompanying

sterile diluent.

If a second dose is administered,

there should be a minimum

interval of 3 months between

doses

Adolescents (13 years of age)

and Adults

Two doses of vaccine, to beadministered with a minimum

interval of 4 weeks between

doses.

Varicella Zoster Immune

Globulin

Injection 125 units

of varicella zoster

immune globulin

antibody

125 units Administer by IV or IM injection

Monitor patient for adverse

effects for at least 20 minutes

after administration of VZIG.

Do notmix with any other drugor solution.

Do notadminister concomitantly

with varicella vaccine.

pre drugs ko

Documents